NYSE:GKOS - Glaukos Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $58.40
  • Forecasted Upside: -30.25 %
  • Number of Analysts: 10
  • Breakdown:
  • 2 Sell Ratings
  • 7 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$83.73
▼ -5.29 (-5.94%)
1 month | 3 months | 12 months
Get New Glaukos Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GKOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GKOS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$58.40
▼ -30.25% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is $58.40, with a high forecast of $80.00 and a low forecast of $36.00. The average price target represents a -30.25% upside from the last price of $83.73.
Hold
The current consensus among 10 polled investment analysts is to hold stock in Glaukos. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 2 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 2 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 3 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 3 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 3 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 2 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 2 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$70.00 ➝ $80.00Low
i
12/16/2020Smith Barney CitigroupUpgradeSell ➝ Neutral$50.00 ➝ $72.00Medium
i
12/16/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgradeSell ➝ Neutral$50.00 ➝ $72.00Medium
i
12/8/2020OppenheimerInitiated CoverageMarket Perform$73.00High
i
11/17/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$68.00Medium
i
11/6/2020Piper SandlerBoost Price TargetOverweight$60.00 ➝ $70.00Low
i
10/8/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$50.00Low
i
8/7/2020Piper SandlerBoost Price TargetPositive ➝ Overweight$50.00 ➝ $60.00High
i
Rating by Matthew O'Brien at Piper Sandler
6/15/2020Jefferies Financial GroupInitiated CoverageHold$44.00Medium
i
5/8/2020Stifel NicolausLower Price TargetHold$55.00 ➝ $45.00Low
i
5/8/2020Piper SandlerLower Price TargetOverweight$62.00 ➝ $50.00Low
i
Rating by Matthew O'Brien at Piper Sandler
5/5/2020JPMorgan Chase & Co.Lower Price TargetNeutral$55.00 ➝ $40.00High
i
Rating by Robert Marcus at JPMorgan Chase & Co.
4/9/2020Piper SandlerReiterated RatingBuyN/A
i
Rating by Matthew O'Brien at Piper Sandler
4/8/2020Wells Fargo & CompanyLower Price TargetUnderweight$53.00 ➝ $34.00High
i
Rating by Larry Biegelsen at Wells Fargo & Company
3/27/2020CitigroupLower Price TargetSell$40.00 ➝ $36.00High
i
3/23/2020StephensLower Price TargetOverweight$69.00 ➝ $44.00High
i
3/4/2020CitigroupInitiated CoverageSell$40.00Medium
i
2/28/2020Stifel NicolausLower Price TargetHold$59.00 ➝ $55.00High
i
2/28/2020Wells Fargo & CompanyLower Price TargetUnderweight$58.00 ➝ $53.00High
i
Rating by Larry Biegelsen at Wells Fargo & Company
2/28/2020StephensLower Price TargetOverweight$80.00 ➝ $69.00High
i
2/28/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$65.00 ➝ $55.00High
i
Rating by Robbie Marcus at JPMorgan Chase & Co.
1/6/2020Berenberg BankUpgradeHold ➝ Buy$60.00 ➝ $65.00N/A
i
12/20/2019JPMorgan Chase & Co.Lower Price TargetOverweight$90.00 ➝ $65.00Medium
i
Rating by Robbie Marcus at JPMorgan Chase & Co.
12/12/2019Wells Fargo & CompanyDowngradeOverweight ➝ Underweight$58.00High
i
10/30/2019BTIG ResearchReiterated RatingHoldLow
i
10/10/2019JPMorgan Chase & Co.Set Price TargetBuy$90.00Low
i
Rating by Robbie Marcus at JPMorgan Chase & Co.
9/30/2019Bank of AmericaDowngradeBuy ➝ Underperform$67.00High
i
8/26/2019JPMorgan Chase & Co.Set Price TargetBuy$90.00Low
i
Rating by Robbie Marcus at JPMorgan Chase & Co.
8/14/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$26.00Low
i
8/13/2019SVB LeerinkReiterated RatingOutperform ➝ Market Perform$25.00 ➝ $22.00High
i
Rating by D. Antalffy at SVB Leerink LLC
8/11/2019BTIG ResearchReiterated RatingHoldHigh
i
8/8/2019CowenDowngradeOutperform ➝ Market Perform$25.00 ➝ $27.00Low
i
5/22/2019BTIG ResearchReiterated RatingNeutral ➝ HoldLow
i
5/10/2019BTIG ResearchReiterated RatingHoldLow
i
5/9/2019BMO Capital MarketsBoost Price TargetMarket Perform$66.00 ➝ $71.00Medium
i
3/20/2019Wells Fargo & CompanyReiterated RatingBuyMedium
i
3/11/2019GuggenheimInitiated CoverageBuy ➝ Buy$21.00High
i
3/11/2019Bank of AmericaInitiated CoverageBuyHigh
i
3/11/2019SVB LeerinkInitiated CoverageOutperform$20.00High
i
Rating by D. Antalffy at SVB Leerink LLC
3/11/2019CowenInitiated CoverageOutperform$20.00Medium
i
3/11/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$16.00Medium
i
3/8/2019BTIG ResearchInitiated CoverageNeutral ➝ Neutral$66.02Low
i
2/28/2019Stifel NicolausBoost Price TargetHold ➝ Positive$58.00 ➝ $68.00High
i
2/28/2019StephensBoost Price TargetOverweight$70.00 ➝ $80.00High
i
2/28/2019Piper Jaffray CompaniesReiterated RatingOverweight$80.00High
i
9/10/2018StephensBoost Price TargetOverweight$57.00 ➝ $70.00Medium
i
9/5/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$59.00 ➝ $68.00Medium
i
8/31/2018Piper Jaffray CompaniesBoost Price TargetOverweight$73.00Low
i
8/30/2018Berenberg BankInitiated CoverageHold ➝ Hold$57.00Medium
i
8/30/2018Wells Fargo & CompanyBoost Price TargetOutperform$50.00 ➝ $74.00High
i
8/30/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$59.00 ➝ $62.00High
i
8/29/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$42.00 ➝ $75.00High
i
Rating by Robert Marcus at JPMorgan Chase & Co.
8/29/2018StephensReiterated RatingOverweight$57.00High
i
8/3/2018Piper Jaffray CompaniesBoost Price TargetOverweight$46.00High
i
8/3/2018Stifel NicolausBoost Price TargetHold ➝ Hold$32.00 ➝ $35.00High
i
7/10/2018BMO Capital MarketsDowngradeOutperform ➝ Market Perform$42.00High
i
6/21/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
i
6/1/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $42.00Medium
i
4/13/2018Stifel NicolausDowngradeBuy ➝ Hold$39.00 ➝ $32.00High
i
3/23/2018Cantor FitzgeraldSet Price TargetBuy$43.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
3/23/2018William BlairReiterated RatingOutperformHigh
i
3/1/2018StephensReiterated RatingBuy$36.00High
i
3/1/2018BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$38.00 ➝ $36.00High
i
3/1/2018William BlairReiterated RatingOutperformHigh
i
3/1/2018Canaccord GenuityLower Price TargetBuy$48.00 ➝ $43.00High
i
2/28/2018Cantor FitzgeraldSet Price TargetBuy ➝ Buy$48.00 ➝ $43.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
2/26/2018Stifel NicolausLower Price TargetBuy ➝ Buy$42.00 ➝ $39.00High
i
1/10/2018Cantor FitzgeraldSet Price TargetBuy$48.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
12/27/2017Cantor FitzgeraldSet Price TargetBuy$48.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
12/11/2017BMO Capital MarketsReiterated RatingBuyLow
i
11/16/2017BMO Capital MarketsLower Price TargetOutperform$40.00 ➝ $38.00N/A
i
11/13/2017StephensReiterated RatingOverweight$47.00 ➝ $40.00N/A
i
11/8/2017BMO Capital MarketsLower Price TargetOutperform$45.00 ➝ $40.00N/A
i
11/7/2017Cantor FitzgeraldReiterated RatingBuy$60.00N/A
i
10/18/2017BMO Capital MarketsReiterated RatingBuy$45.00N/A
i
9/15/2017StephensReiterated RatingBuy$47.00Medium
i
9/15/2017Piper Jaffray CompaniesReiterated RatingPositive ➝ Buy$38.00High
i
9/14/2017Stifel NicolausReiterated RatingBuyHigh
i
9/14/2017Cantor FitzgeraldReiterated RatingBuy$54.00 ➝ $60.00High
i
9/1/2017BMO Capital MarketsReiterated RatingBuy$54.00N/A
i
8/3/2017Piper Jaffray CompaniesReiterated RatingBuy$56.00Medium
i
8/3/2017Roth CapitalLower Price TargetBuy$60.00 ➝ $54.00High
i
5/8/2017StephensUpgradeEqual Weight ➝ OverweightLow
i
5/4/2017Cantor FitzgeraldReiterated RatingOverweight$54.00High
i
4/11/2017BMO Capital MarketsReiterated RatingBuy$54.00Medium
i
3/2/2017Cantor FitzgeraldBoost Price TargetOverweight$45.00 ➝ $54.00N/A
i
2/28/2017Stifel NicolausBoost Price TargetPositive$45.00 ➝ $55.00N/A
i
2/22/2017BMO Capital MarketsInitiated CoverageOutperform$54.00N/A
i
1/6/2017Stifel NicolausUpgradeHold ➝ Buy$42.00 ➝ $45.00N/A
i
11/30/2016Cantor FitzgeraldReiterated RatingBuy$41.00 ➝ $45.00N/A
i
11/11/2016Cantor FitzgeraldBoost Price Target$45.00N/A
i
10/27/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
9/27/2016Stifel NicolausReiterated RatingHoldN/A
i
9/25/2016Cantor FitzgeraldReiterated RatingBuy$41.00N/A
i
8/2/2016Roth CapitalBoost Price TargetBuy$36.50 ➝ $41.00N/A
i
8/2/2016Piper Jaffray CompaniesBoost Price Target$42.00N/A
i
8/2/2016Cantor FitzgeraldBoost Price TargetBuy$35.00 ➝ $41.00N/A
i
8/1/2016Piper Jaffray CompaniesReiterated RatingOverweight$27.00 ➝ $40.00N/A
i
7/17/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
6/2/2016Cantor FitzgeraldInitiated CoverageNot Available ➝ Buy$35.00N/A
i
Rating by E. Piros at Cantor Fitzgerald
5/25/2016Piper Jaffray CompaniesReiterated RatingOverweight$27.00N/A
i
5/4/2016Piper Jaffray CompaniesReiterated RatingBuy$21.00 ➝ $27.00N/A
i
5/4/2016Roth CapitalBoost Price TargetBuy$24.00 ➝ $30.00N/A
i
4/23/2016Piper Jaffray CompaniesReiterated RatingBuy$21.00N/A
i
4/14/2016Roth CapitalInitiated CoverageBuy$24.00N/A
i
Rating by C. Lewis at Roth Capital
4/8/2016Stifel NicolausInitiated CoverageHoldN/A
i
3/24/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
(Data available from 3/4/2016 forward)
Glaukos logo
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; iDose Travoprost, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication; and MicroShunt, an ab-externo device for treatment of open-angle glaucoma. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.
Read More

Today's Range

Now: $83.73
$82.26
$88.28

50 Day Range

MA: $91.37
$77.99
$97.42

52 Week Range

Now: $83.73
$23.31
$99.00

Volume

519,495 shs

Average Volume

452,095 shs

Market Capitalization

$3.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Glaukos?

The following sell-side analysts have issued stock ratings on Glaukos in the last year: Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Jefferies Financial Group Inc., JPMorgan Chase & Co., Oppenheimer Holdings Inc., Piper Sandler, Smith Barney Citigroup, Stephens, Stifel Nicolaus, TheStreet, and Wells Fargo & Company.
View the latest analyst ratings for GKOS.

What is the current price target for Glaukos?

10 Wall Street analysts have set twelve-month price targets for Glaukos in the last year. Their average twelve-month price target is $58.40, suggesting a possible downside of 30.3%. Piper Sandler has the highest price target set, predicting GKOS will reach $80.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $36.00 for Glaukos in the next year.
View the latest price targets for GKOS.

What is the current consensus analyst rating for Glaukos?

Glaukos currently has 2 sell ratings, 7 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GKOS, but not buy more shares or sell existing shares.
View the latest ratings for GKOS.

What other companies compete with Glaukos?

How do I contact Glaukos' investor relations team?

Glaukos' physical mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier's listed phone number is 949-367-9600 and its investor relations email address is [email protected] The official website for Glaukos is www.glaukos.com.